The Castilla-La Mancha Management Council has authorized a contract for the supply of monoclonal antibodies against the disease caused by the Respiratory Syncytial Virus (RSV) for the 2023-2024 season of Castilla-La Mancha freshmen Immunization of children and infants.in the amount of EUR 3,260,400.
Esther Padilla, spokeswoman for the Castilla-Latin administration, explained that respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children under one year old, especially in connection with bronchiolitis Infections associated with pneumonia, and the adult population over the age of 65 and those at risk.
As a result, Padilla insisted that “the first priority is to prevent disease and take care of the health of all citizens” and reduce the severe nursing overload that occurs in primary care services and hospitals every winter.
On October 31, 2022, the European Commission authorized Beyfortus for the prevention of lower respiratory disease caused by RSV in newborns and infants during the first season of exposure to the virus.
In adults and older children, RSV infection may be asymptomatic or manifest as sinusitis or the common cold. In addition, babies may become fussy, have difficulty breathing, and become less active.